To date, more than 15,680 lawsuits have been filed across the country against the makers and distributors of Xarelto. Of those cases, more than 14,000 are pending in New Orleans, La., in the multi-district litigation (MDL 2592) overseen by U.S. District Court Judge Eldon Fallon. Beasley Allen lawyer Andy Birchfield serves as Co-Lead Counsel for the Plaintiffs Steering Committee. There are also approximately 1,285 state court cases pending in the Philadelphia Court of Common Pleas, Pennsylvania and additional state court cases pending in Delaware, California and Missouri.
On Sept. 21, 2016, the MDL Court entered Case Management Order No. 2A, amending CMO No. 2 to reset bellwether trial dates and deadlines. The first Xarelto MDL Bellwether trial is scheduled to begin on March 13, 2017. In Pennsylvania state court, Judge Arnold New (presiding over the Philadelphia Court of Common Pleas) consolidated Xarelto litigation, and directed the parties to select 10 Bellwether cases from the pool of more than 1,000 filed cases and get them ready for trial starting in the Summer of 2017. The outcomes of bellwether trials can provide insight into how other juries might rule in similar lawsuits, and potentially help bring an entire litigation to resolution.
Xarelto is a blood thinner manufactured by German drug maker Bayer AG and distributed in the U.S. by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Xarelto entered the U.S. market in July 2011, and is currently approved for six indications, including reducing the risk of stroke in patients with non-valvular atrial fibrillation; treating deep vein thrombosis and pulmonary embolism, and reducing the recurrence of these conditions; and preventing blood clots in patients following knee or hip replacement surgery.
Xarelto carries a significant risk of severe, uncontrolled internal bleeding, with bleeding most often occurring in the gastrointestinal tract or brain. Xarelto has been linked to gastrointestinal bleeds, brain bleeds and bleeding deaths, and, unlike warfarin, there is currently no antidote to reverse the blood thinning qualities of Xarelto in the event of a bleeding emergency. Xarelto carries many black box warnings, the most serious kind issued by the U.S. Food and Drug Administration (FDA).
According to the Institute of Safe Medication Practices, data from the FDA shows that Xarelto accounted for the largest number of reported cases of domestic, serious injury among regularly monitored drugs in 2015. In 2015, there was a total of 10,674 reports involving patients on Xarelto, including 1,121 patient deaths and 4,508 injuries requiring hospitalization. The most frequent reports involved bleeding on the brain and in the intestines.
For more information, you can contact Melissa Prickett, a lawyer in our firm’s Mass Torts Section, at 334-269-2343 or 800-898-2034, or email email@example.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.